Mather Group’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Mather Group’s Portfolio IHE Stock Details IHE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$73.6K	Buy	743 +216	+41%	+$19.5K	﹤0.01%	1012
2026 Q1	$45.7K	Buy	+527	New	+$46.1K	﹤0.01%	1076
2025 Q4	–	Sell	-527	Closed	-$38.2K	–	1114
2025 Q3	$38.2K	Buy	+527	New	+$36.4K	﹤0.01%	974
2025 Q2	–	Sell	-429	Closed	-$30.3K	–	1131
2025 Q1	$30.3K	Hold	429	–	–	﹤0.01%	997
2024 Q4	$28.2K	Hold	429	–	–	﹤0.01%	991
2024 Q3	$30.3K	Hold	429	–	–	﹤0.01%	970
2024 Q2	$29.1K	Buy	+429	New	+$28.1K	﹤0.01%	1153

Other funds holding IHE

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

IWS

Insight Wealth Strategies San Ramon, California $1.02B AUM 38% 1-Year Est. Return

Mather Group's IHE Position: Q2 2026 in Review

Mather Group increased its iShares US Pharmaceuticals ETF (IHE) stake by 41% in Q2 2026, buying an estimated $19.5K and bringing the position to 743 shares worth $73.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1012.

Mather Group first reported a position in IHE in Q2 2024 and has held it in 7 quarters since. 209 funds tracked by Wall St. Rank hold IHE as of Q2 2026.

Mather Group held 743 shares of iShares US Pharmaceuticals ETF worth $73.6K as of Q2 2026.
Mather Group bought 216 iShares US Pharmaceuticals ETF shares in Q2 2026, an estimated $19.5K.
iShares US Pharmaceuticals ETF made up ﹤0.01% of Mather Group's portfolio in Q2 2026, its #1012 holding.
Mather Group first reported a position in iShares US Pharmaceuticals ETF in Q2 2024 and has held it in 7 quarters since.
209 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q2 2026.

Based on Mather Group's 13F filing for Q2 2026, filed 27 Jul 2026.